This biotech leader could be poised to rally higher.Amgen (AMGN -0.09%) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant and Dow Jones Industrial Average component, pending clinical-trial data from its drug pipeline has added a layer of uncertainty.On the other hand, the company continues to deliver strong growth with overall positive fundamentals. So is now a good time to pick up so ...

The latest trading session saw Amgen (AMGN) ending at $325.09, denoting a +0.14% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%.Shares of the world's largest biotech drugmaker have depreciated by 3.17% over the course of the past month, outperforming the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.The investment comm ...

MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ PatientsFirst and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid UseTHOUSAND OAKS, Calif., Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with generalized myasthenia gravis (gMG), a ...

Income stocks can be wise additions to your portfolio in any market environment.Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your overall returns. Whether you use that cash to reinvest or put it aside for a rainy day, dividend stocks can be an excellent addition to any portfolio and for investors with a variety of investment styles.If you're hunting for two top dividend stocks to add to your portfolio right now, here are a couple of ...

These longtime leading biotech stocks still have plenty of upside ahead.October typically isn't a time investors look forward to in the markets. It has historically been associated with equities moving in the wrong direction, and sometimes experiencing full-blown market crashes. The broader market has performed pretty well so far this year, but could that come to a halt in October? Maybe.No matter what happens, investing in companies that will get through bear markets and perform well over the long run is a ...

Investing in the most popular players in the space isn't the only valid approach.The ecosystem of companies competing to develop therapies for weight loss is growing every day, and there's more than one competitor that's investment-ready. While many investors look to small and risky biotechs to get exposure, there are larger and safer options, too.Today, we'll discuss two such options. Neither is a leader in the weight loss space just yet, but with promising irons in the fire, they're positioned to have a s ...

Amgen (AMGN) closed at $319.66 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.The the stock of world's largest biotech drugmaker has fallen by 2.12% in the past month, leading the Medical sector's loss of 4.05% and undershooting the S&P 500's gain of 3.15%.The investment community will be paying close attention to the earnings performance of Amgen in its upcom ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation ...

Shares of Amgen (AMGN) fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the autoimmune disease space. While the studies did meet their respective primary endpoints, Wall Street termed the results ‘lackluster’ and ‘underwhelming’.At a conference call on Tuesday, Amgen posted top-line data from two late-stage studies — HORIZON and MINT. The HORIZON study evaluated an investigational anti-OX40 therapy rocatinlimab in atopic dermatitis (AD or eczema) indication. In the ...